Declared Dividend • May 25
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 27th May 2026 Payment date: 27th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 9.1% per year over the past 4 years. However, payments have been volatile during that time. EPS is expected to grow by 59% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Apr 24
Mingyue Optical Lens Co.,Ltd. (SZSE:301101) signed a letter of intent to acquire 16.80% stake in Jiangsu Binde Optical Co., Ltd. from Shanghai Lizheng Optical Eyewear Co., Ltd. for CNY 19.1 million. Mingyue Optical Lens Co.,Ltd. (SZSE:301101) signed a letter of intent to acquire 16.80% stake in Jiangsu Binde Optical Co., Ltd. from Shanghai Lizheng Optical Eyewear Co., Ltd. for CNY 19.1 million on April 21, 2026. A cash consideration of CNY 19.11 million will be paid by Mingyue Optical Lens Co.,Ltd. As part of consideration, CNY 19.11 million is paid towards common equity of Jiangsu Binde Optical Co., Ltd. . The transaction will be financed through its own funds of CNY 19.11 million. The Board agreed that the Company would enter into an Equity Transfer Agreement with relevant parties.
For the period ending December 31, 2025, Jiangsu Binde Optical Co., Ltd. reported total revenue of CNY 82.74 million, EBIT of CNY 12.64 million and net income of CNY 9.36 million. As of December 31, 2025, Jiangsu Binde Optical Co., Ltd. reported total assets of CNY 106.95 million and total common equity of CNY 30.33 million.
The transaction is approved by acquirer board. Reported Earnings • Apr 24
First quarter 2026 earnings released: EPS: CN¥0.28 (vs CN¥0.23 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.28 (up from CN¥0.23 in 1Q 2025). Revenue: CN¥233.3m (up 18% from 1Q 2025). Net income: CN¥56.1m (up 19% from 1Q 2025). Profit margin: 24% (in line with 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Apr 23
Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 15, 2026 Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: 3F, Tower B, No. 567, Langao Road, Putuo District, Shanghai China Price Target Changed • Apr 07
Price target decreased by 20% to CN¥40.00 Down from CN¥50.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of CN¥32.69. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥0.99 for next year compared to CN¥0.88 last year. Announcement • Mar 31
Mingyue Optical Lens Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Mingyue Optical Lens Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Announcement • Dec 31
Mingyue Optical Lens Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Mingyue Optical Lens Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 27
Third quarter 2025 earnings released: EPS: CN¥0.27 (vs CN¥0.24 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.27 (up from CN¥0.24 in 3Q 2024). Revenue: CN¥227.2m (up 15% from 3Q 2024). Net income: CN¥53.6m (up 12% from 3Q 2024). Profit margin: 24% (in line with 3Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Mingyue Optical Lens Co.,Ltd. to Report Q3, 2025 Results on Oct 27, 2025 Mingyue Optical Lens Co.,Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025 Reported Earnings • Aug 28
Second quarter 2025 earnings released: EPS: CN¥0.24 (vs CN¥0.23 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.24 (up from CN¥0.23 in 2Q 2024). Revenue: CN¥202.0m (up 4.7% from 2Q 2024). Net income: CN¥48.4m (up 3.4% from 2Q 2024). Profit margin: 24% (in line with 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Jul 02
Mingyue Optical Lens Co.,Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Mingyue Optical Lens Co.,Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Valuation Update With 7 Day Price Move • May 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥42.01, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 42% over the past three years. Declared Dividend • May 21
Dividend increased to CN¥0.50 Dividend of CN¥0.50 is 67% higher than last year. Ex-date: 23rd May 2025 Payment date: 23rd May 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (81% cash payout ratio). The dividend has increased by an average of 12% per year over the past 3 years. However, payments have been volatile during that time. EPS is expected to grow by 59% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Apr 19
Mingyue Optical Lens Co.,Ltd. Proposes Final Cash Dividend for 2024 Mingyue Optical Lens Co.,Ltd. proposed final cash dividend of CNY 5.00000000 per 10 shares (tax included) for 2024. Reported Earnings • Apr 18
First quarter 2025 earnings released: EPS: CN¥0.23 (vs CN¥0.21 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.23 (up from CN¥0.21 in 1Q 2024). Revenue: CN¥197.1m (up 2.6% from 1Q 2024). Net income: CN¥47.1m (up 12% from 1Q 2024). Profit margin: 24% (up from 22% in 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 18
Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 13, 2025 Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 13, 2025, at 14:30 China Standard Time. Location: 3F, No. 567, Langao Road, Putuo District, Shanghai China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥44.81, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 20x in the Medical Equipment industry in China. Total returns to shareholders of 101% over the past three years. Announcement • Mar 31
Mingyue Optical Lens Co.,Ltd. to Report Q1, 2025 Results on Apr 18, 2025 Mingyue Optical Lens Co.,Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025 Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥55.91, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 20x in the Medical Equipment industry in China. Total returns to shareholders of 91% over the past three years. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥47.66, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 54% over the past three years. Announcement • Dec 31
Mingyue Optical Lens Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025 Mingyue Optical Lens Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025 Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥47.55, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥40.00, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 3.5% over the past year. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥28.89, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 19% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥13.14 per share. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.21 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.24 (up from CN¥0.21 in 3Q 2023). Revenue: CN¥198.3m (flat on 3Q 2023). Net income: CN¥48.0m (up 14% from 3Q 2023). Profit margin: 24% (up from 22% in 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥24.92, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥11.20 per share. Announcement • Sep 30
Mingyue Optical Lens Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Mingyue Optical Lens Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to CN¥27.55, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 26% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥11.17 per share. Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥22.67, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥11.18 per share. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.23 (up from CN¥0.22 in 2Q 2023). Revenue: CN¥192.9m (flat on 2Q 2023). Net income: CN¥46.8m (up 3.7% from 2Q 2023). Profit margin: 24% (in line with 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to CN¥26.98, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 27% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.28 per share. Buy Or Sell Opportunity • Aug 13
Now 30% overvalued Over the last 90 days, the stock has fallen 17% to CN¥22.48. The fair value is estimated to be CN¥17.29, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 52% in the next 2 years. Price Target Changed • Jul 24
Price target decreased by 7.9% to CN¥35.95 Down from CN¥39.05, the current price target is an average from 2 analysts. New target price is 70% above last closing price of CN¥21.14. Stock is down 48% over the past year. The company is forecast to post earnings per share of CN¥0.97 for next year compared to CN¥0.78 last year. Announcement • Jun 29
Mingyue Optical Lens Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024 Mingyue Optical Lens Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024 Declared Dividend • May 23
Dividend of CN¥0.30 announced Shareholders will receive a dividend of CN¥0.30. Ex-date: 28th May 2024 Payment date: 28th May 2024 Dividend yield will be 1.1%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (37% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 73% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.17 in 1Q 2023). Revenue: CN¥192.1m (up 12% from 1Q 2023). Net income: CN¥42.2m (up 20% from 1Q 2023). Profit margin: 22% (up from 20% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Apr 23
Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 14, 2024 Mingyue Optical Lens Co.,Ltd., Annual General Meeting, May 14, 2024, at 14:30 China Standard Time. Location: 3F, No. 567, Langao Road, Putuo District, Shanghai China Announcement • Mar 30
Mingyue Optical Lens Co.,Ltd. to Report Q1, 2024 Results on Apr 23, 2024 Mingyue Optical Lens Co.,Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥27.56, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 36% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.41 per share. Announcement • Dec 29
Mingyue Optical Lens Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Mingyue Optical Lens Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024 Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥35.97, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.12 per share. Announcement • Oct 28
Mingyue Optical Lens Co.,Ltd. (SZSE:301101) announces an Equity Buyback for CNY 30 million worth of its shares. Mingyue Optical Lens Co.,Ltd. (SZSE:301101) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 53.02 per share. The shares purchased will be used for the company's equity incentive plan or ESOP. The program will be valid till 12 months. Price Target Changed • Oct 24
Price target decreased by 9.3% to CN¥51.73 Down from CN¥57.03, the current price target is an average from 2 analysts. New target price is 51% above last closing price of CN¥34.21. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.85 for next year compared to CN¥0.68 last year. Reported Earnings • Oct 24
Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥197.0m (up 17% from 3Q 2022). Net income: CN¥42.3m (up 21% from 3Q 2022). Profit margin: 22% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Sep 30
Mingyue Optical Lens Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023 Mingyue Optical Lens Co.,Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023 New Risk • Aug 09
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Short dividend paying track record (1 year of continuous dividend payments). Reported Earnings • Aug 08
Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.15 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.15 in 2Q 2022). Revenue: CN¥194.3m (up 29% from 2Q 2022). Net income: CN¥45.1m (up 50% from 2Q 2022). Profit margin: 23% (up from 20% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jul 01
Mingyue Optical Lens Co.,Ltd. to Report First Half, 2023 Results on Aug 08, 2023 Mingyue Optical Lens Co.,Ltd. announced that they will report first half, 2023 results on Aug 08, 2023 Price Target Changed • May 18
Price target increased by 11% to CN¥85.55 Up from CN¥77.29, the current price target is an average from 2 analysts. New target price is 21% above last closing price of CN¥70.90. Stock is up 86% over the past year. The company is forecast to post earnings per share of CN¥1.27 for next year compared to CN¥1.01 last year. Announcement • May 17
Mingyue Optical Lens Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 23, 2023 Mingyue Optical Lens Co.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is May 22, 2023. Ex-date is May 23, 2023. Payment date is May 23, 2023. Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥65.99, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in China. Total returns to shareholders of 122% over the past year. Reported Earnings • Apr 19
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: CN¥1.01 (up from CN¥0.81 in FY 2021). Revenue: CN¥623.1m (up 8.3% from FY 2021). Net income: CN¥136.2m (up 66% from FY 2021). Profit margin: 22% (up from 14% in FY 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2021). Revenue: CN¥168.3m (up 11% from 3Q 2021). Net income: CN¥35.0m (up 46% from 3Q 2021). Profit margin: 21% (up from 16% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥54.38, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.17 per share. Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.21 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.21 in 2Q 2021). Revenue: CN¥150.2m (flat on 2Q 2021). Net income: CN¥30.1m (up 43% from 2Q 2021). Profit margin: 20% (up from 14% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 26% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥46.41, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 23x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥39.12 per share. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥51.33, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 24x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥39.52 per share. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥44.90, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 22x in the Medical Equipment industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥39.40 per share. Announcement • May 20
Mingyue Optical Lens Co.,Ltd. Announces Implementation of 2021 Final Profit Distribution Plan, Payable on 25 May 2022 Mingyue Optical Lens Co.,Ltd. announced 2021 final profit distribution plan to be implemented (A shares) as cash dividend (tax included) of CNY 5.30000000 per ten shares. The record date is 24 May 2022, ex-date is 25 May 2022, and payment date is on 25 May 2022. Announcement • May 19
Mingyue Optical Lens Co.,Ltd. Approves Cash Dividend for the Year 2021 Mingyue Optical Lens Co.,Ltd. approved cash dividend of CNY 5.30000000 (tax included) per 10 shares for 2021, at the AGM held on May 16, 2022. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥34.88, the stock trades at a trailing P/E ratio of 51.4x. Average trailing P/E is 29x in the Medical Equipment industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Apr 26
Mingyue Optical Lens Co.,Ltd. Proposes Cash Dividend for 2021 Mingyue Optical Lens Co.,Ltd. proposed cash dividend of CNY 5.30000000 (tax included) per 10 shares for 2021. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥34.34, the stock trades at a trailing P/E ratio of 55.8x. Average trailing P/E is 31x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥41.22, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 34x in the Medical Equipment industry in China.